Nucleix Adds $55M To Support EpiCheck Lung Cancer Test

The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.

Lung Cancer
• Source: shutterstock.com

Nucleix has completed a $55M funding round to advance its Lung EpiCheck liquid-biopsy test for the early detection of lung cancer.

The oversubscribed funding round, announced on 7 April, is led by RA Capital Management, with participation from BlackRock, Lilly Asia...

More from Financing

More from Business